Provided are crystalline , -disubstituted amino acids and their crystalline salts containing a terminal alkene on one of their side chains, as well as optionally crystalline halogenated and deuterated analogs of the , -disubstituted amino acids and their salts; methods of making these, and methods of using these.

Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one aromatic amine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one alkylated amine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.

The present invention provides a method for acylating one or more amino groups of a peptide where the acylation reaction is to be performed in an aqueous mixture containing less than 10% w/w aprotic polar solvent.

An improved method of producing a peptide molecule as set forth in SEQ ID NO: 1 (DGSVVVNKVSELPAGHGLNVNTLSYGDLAAD) is described herein. According to some embodiments of the present disclosure, the method includes: forming a peptide by solid phase peptide synthesis (SPPS) on a resin; cleaving and deprotecting the peptide on the resin to form a crude product; purifying the crude product by column chromatography to collect eluant fractions; concentrating the eluant fractions to form a concentrated eluate; and isolating the peptide molecule from the concentrated eluate by precipitation and filtration.

The present invention relates to methods of producing a synthetic peptide or pharmaceutically acceptable salts thereof of SEQ ID NO: 1.

The invention described herein includes a novel platform for the development of novel shapeshifting drug-like compounds that overcome physical mass limitations as they possess the ability to interconvert internally and spontaneously, i.e., shapeshift, between multiple chemical structures with varying pharmacophore properties. In one preferred embodiment, the invention include systems, methods, and compositions for the synthesis of novel bullvalene amino acid (Bvas) compounds that may further be incorporated into Shape Shifting Cyclic Peptides (SSCP) with varying pharmacophore properties and their use as novel therapeutic compounds.

Tetrazine non-canonical amino acids, methods for making the tetrazine non-canonical amino acids, methods for incorporating the tetrazine non-canonical amino acids into proteins and polypeptides, post-translationally modified proteins and polypeptides in which the tetrazine non-canonical amino acids have been incorporated, and kits for incorporating the tetrazine non-canonical amino acids into proteins and polypeptides.

The invention described herein includes a novel platform for the development of novel shapeshifting drug-like compounds that overcome physical mass limitations as they possess the ability to interconvert internally and spontaneously, i.e., shapeshift, between multiple chemical structures with varying pharmacophore properties. In one preferred embodiment, the invention include systems, methods, and compositions for the synthesis of novel bullvalene amino acid (Bvas) compounds that may further be incorporated into Shape Shifting Cyclic Peptides (SSCP) with varying pharmacophore properties and their use as novel therapeutic compounds.

Vaccine compositions comprising a plurality of immunogens attached to a carrier for inducing an immune response against a pathogen selected from the Anaplasma, Babesia, Borrelia, and Chlamydia genera. Vaccine compositions comprising multivalent carriers and related methods using the vaccine compositions in various therapeutic and prophylactic applications for inducing an immune response against, treating, or preventing an infection caused by the Anaplasma, Babesia, Borrelia, or Chlamydia pathogens, and the related diseases thereof.

Methodology was developed for transformation of methionine residues into homocysteine derivatives. Methionine residues can undergo alkylation reactions at low pH to yield sulfonium ions, which can then be selectively demethylated to give alkyl homocysteine residues. This process tolerates many functional groups.